Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024 [Yahoo! Finance]
Elevation Oncology, Inc. - Common stock (ELEV)
Company Research
Source: Yahoo! Finance
BOSTON March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, today announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California "We are excited to share preclinical proof-of-concept data for our HER3-ADC program. HER3 is a clinically validated oncology and ADC target, which is overexpressed across a range of solid tumors, and is often associated with a poor clinical outcome," said David Dornan , Ph.D., Chief Scientific Officer of Elevation Oncology. "At AACR, we plan to share preclinical proof-of-concept data highlighting our progress towards the development of
Show less
Read more
Impact Snapshot
Event Time:
ELEV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELEV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELEV alerts
High impacting Elevation Oncology, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ELEV
News
- Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling [Seeking Alpha]Seeking Alpha
- Elevation Oncology, Inc. (NASDAQ: ELEV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.MarketBeat
- Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]Yahoo! Finance
- Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsPR Newswire
- Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade) [Seeking Alpha]Seeking Alpha
ELEV
Sec Filings
- 5/2/24 - Form S-3
- 5/2/24 - Form 8-K
- 5/2/24 - Form 10-Q
- ELEV's page on the SEC website